PREVENTION OF ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKER
B-肾上腺素能阻滞剂预防食管静脉曲张
基本信息
- 批准号:3247981
- 负责人:
- 金额:$ 40.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-04-01 至 1998-03-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Cirrhosis is the fourth leading cause of death in the United States in
individuals under the age of 65, the productive years of life. It
affects men and women equally, and impacts on all races and socio-
economical levels. Portal hypertension is the main complication of
cirrhosis, regardless of etiology. Gastroesophageal varices and variceal
hemorrhage are a direct consequence of portal hypertension and account
in large part for the high mortality of cirrhosis. Varices result from
porto-systemic collaterals that develop as portal pressure increases.
Non-selective beta-adrenergic blockers decrease portal
pressure and have been shown to prevent the first variceal
hemorrhage in patients with cirrhosis and varices. However, a
beneficial effect on survival has not been clearly demonstrated. This
is probably related to the advanced stage of cirrhosis at the time beta-
blocker therapy is initiated, since in these studies patients already
have varices and frequently have ascites. Experimental studies have
shown that propranolol therapy, administered in the early stages of
portal hypertension, can prevent the development of porto-systemic
collaterals. Early portal hypotensive therapy would be beneficial not
only because it may prevent or delay the formation of varices (and
consequently of variceal hemorrhage), but because it may prevent or delay
the development of other complications of portal hypertension, such as
ascites and porto-systemic encephalopathy.
This trial is designed as a prospective, randomized, placebo-controlled,
double-blind trial of 212 patients with cirrhosis and portal
hypertension. Its primary aim is to investigate if early beta-adrenergic
therapy can prevent or delay the development of gastroesophageal varices
in patients with cirrhosis and portal hypertension. Secondary aims will
examine whether this therapy prevents or delays other complications of
portal hypertension such as ascites and porto-systemic encephalopathy,
as well as liver transplantation or death. Patients with cirrhosis,
without varices on endoscopy and with a portal pressure of greater than
or equal to 6 mmHg will be included and will be followed for up to 5
years. In planning the trial, we assumed a rate of development of
varices of 50% at 4 years. The calculated sample size of 2123 ensures
high statistical power (80%) to detect a reduction in varices to 30% in
the propranolol group. The trial is highly significant for the promise
it holds for the treatment of cirrhosis of all etiologies and for an
understanding of the natural history of the disease. The four centers
involved are widely renown for their studies in this area and have
collaborated productively in the past, including the only published
double-blind trial of propranolol in the prevention of first variceal
hemorrhage in patients with cirrhosis and varices.
肝硬化是美国第四大死亡原因,
65岁以下的人,生命的生产年数。 它
对男女的影响是平等的,对所有种族和社会都有影响,
经济水平。 门静脉高压症是肝硬化的主要并发症,
肝硬化,不论病因。 胃食管静脉曲张
出血是门静脉高压直接后果,
在很大程度上是因为肝硬化的高死亡率。 静脉曲张是由
随着门静脉压力增加而形成的门体侧支循环。
非选择性β-肾上腺素能受体阻滞剂减少门静脉
压力,并已被证明可以防止第一次静脉曲张
肝硬化和静脉曲张患者出血。 但
对生存的有益影响尚未得到明确证实。 这
很可能与肝硬化晚期有关
开始阻滞剂治疗,因为在这些研究中,
有静脉曲张,经常有腹水。 实验研究
表明在早期阶段给予普萘洛尔治疗,
门静脉高压症,可防止门体循环的发展
侧枝。 早期门静脉扩张治疗是有益的,
只是因为它可以防止或延迟静脉曲张的形成(和
但由于它可以防止或延迟
门静脉高压症的其他并发症的发展,如
腹水和门体脑病。
本试验设计为前瞻性、随机、安慰剂对照,
212例肝硬化门脉高压患者的双盲试验
高血压 其主要目的是研究早期β-肾上腺素能
治疗可以预防或延缓胃食管静脉曲张的发展
肝硬化和门静脉高压症患者。 次要目标将
检查这种疗法是否可以预防或延迟其他并发症,
门静脉高压症如腹水和门体脑病,
以及肝移植或死亡。 肝硬化患者,
内镜检查无静脉曲张,门静脉压力大于
或等于6 mmHg,并将随访最多5
年 在计划试验时,我们假设
4年时静脉曲张50%。 计算的样本量为2123,
检测静脉曲张减少至30%的统计功效较高(80%),
普萘洛尔组。 这次审判对于实现
它适用于所有病因的肝硬化的治疗,
了解疾病的自然史。 四个中心
参与者因其在这一领域的研究而闻名,
在过去的合作富有成效,包括唯一出版的
普萘洛尔预防首次静脉曲张的双盲试验
肝硬化和静脉曲张患者出血。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERTO J GROSZMANN其他文献
ROBERTO J GROSZMANN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERTO J GROSZMANN', 18)}}的其他基金
OCTREOTIDE EFFECT ON SODIUM BALANCE/SYSTEMIC HEMODYNAMICS IN CIRRHOSIS & ASCITES
奥曲肽对肝硬化患者钠平衡/全身血流动力学的影响
- 批准号:
6306179 - 财政年份:1999
- 资助金额:
$ 40.6万 - 项目类别:
OCTREOTIDE EFFECT ON SODIUM BALANCE/SYSTEMIC HEMODYNAMICS IN CIRRHOSIS & ASCITES
奥曲肽对肝硬化患者钠平衡/全身血流动力学的影响
- 批准号:
6116065 - 财政年份:1998
- 资助金额:
$ 40.6万 - 项目类别:
OCTREOTIDE EFFECT ON SODIUM BALANCE/SYSTEMIC HEMODYNAMICS IN CIRRHOSIS & ASCITES
奥曲肽对肝硬化患者钠平衡/全身血流动力学的影响
- 批准号:
6277299 - 财政年份:1997
- 资助金额:
$ 40.6万 - 项目类别:
ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
B-肾上腺素能阻滞剂治疗食管静脉曲张
- 批准号:
6380796 - 财政年份:1993
- 资助金额:
$ 40.6万 - 项目类别:
ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
B-肾上腺素能阻滞剂治疗食管静脉曲张
- 批准号:
6517263 - 财政年份:1993
- 资助金额:
$ 40.6万 - 项目类别:
ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
B-肾上腺素能阻滞剂治疗食管静脉曲张
- 批准号:
2900276 - 财政年份:1993
- 资助金额:
$ 40.6万 - 项目类别:
PREVENTION OF ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKER
B-肾上腺素能阻滞剂预防食管静脉曲张
- 批准号:
2145813 - 财政年份:1993
- 资助金额:
$ 40.6万 - 项目类别:
PREVENTION OF ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKER
B-肾上腺素能阻滞剂预防食管静脉曲张
- 批准号:
2145812 - 财政年份:1993
- 资助金额:
$ 40.6万 - 项目类别:
ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
B-肾上腺素能阻滞剂治疗食管静脉曲张
- 批准号:
6176227 - 财政年份:1993
- 资助金额:
$ 40.6万 - 项目类别:
ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
B-肾上腺素能阻滞剂治疗食管静脉曲张
- 批准号:
2614182 - 财政年份:1993
- 资助金额:
$ 40.6万 - 项目类别: